Damemarie Paul, MPH1, Ye Wang, PhD1, Jasjit Multani, MPH2, Marie Yasuda, PharmD, MS3, Yifan Gu, MS2, Ching An Wang, MA1, Anand K Srirampurapu, MBA4, Chi-Chang Chen, PhD, PharmD, MS3 1Bristol Myers Squibb, Princeton, NJ; 2IQVIA, Durham, NC; 3IQVIA, Wayne, PA; 4Mu Sigma, Bengaluru, Karnataka, India
Introduction: 5-aminosalicylic acid (5-ASA), taken 3 times daily, is recommended to treat moderate ulcerative colitis (UC). Lack of sustained treatment response is often due to poor adherence, which is generally associated with less severe disease, pill burden, and young age. In real-world settings, 6-month adherence rates for 5-ASA are reported to be 40–50%. Ozanimod (OZA), a once-daily pill, has shown clinical benefit, regardless of patient exposure to advanced therapy (AT). This study describes real-world OZA adherence rates for commercially insured patients with UC.
Methods: Adult patients, identified from the IQVIA Longitudinal Access and Adjudication Database from April 2020 to October 2023, with a confirmed UC diagnosis and ≥1 OZA prescription at index (first prescription date) were included in this study. All patients had ≥12 months of data visibility pre-index and ≥6 months of data visibility post-index. Patients were excluded if they had Crohn’s disease or multiple sclerosis, any type of malignancy at baseline, received multiple ATs at index, or only had an OZA 7-day starter pack. To determine disease severity, patients were categorized based on prescription information before OZA initiation, as AT-naive if there was no evidence of prior AT use, or AT-experienced if there was evidence of prior AT use, along with other indicators of severe disease (ie, pancolitis and corticosteroid use). Adherence, reported as the proportion of days covered (PDC) by OZA prescription, was measured over a 6-month post-index period (PDC ≥80% = adherent).
Results: The study included 688 patients, most of whom were male (55.2%) and AT-naive (56.4%). Median age (interquartile range) was 43.5 (32.0–57.0) years. Compared with AT-experienced patients, fewer AT-naive patients (51.3% vs 36.9%, respectively) had indicators of severe disease. Length of treatment with corticosteroid was also shorter in AT-naive patients (144.7 days) vs AT-experienced patients (222.5 days). The median adherence rate was 82.0% in both groups. Within 6 months of OZA initiation, 6.7% of AT-naive patients and 8.3% of AT-experienced patients had discontinued treatment.
Discussion: Patients taking OZA for the treatment of UC were predominantly AT-naive, were aged < 50 years, and had less severe disease indicators. High adherence rates to ozanimod (82%) were notable in a population with risk factors for a traditionally low adherence to 5-ASA.
Damemarie Paul, MPH1, Ye Wang, PhD1, Jasjit Multani, MPH2, Marie Yasuda, PharmD, MS3, Yifan Gu, MS2, Ching An Wang, MA1, Anand K Srirampurapu, MBA4, Chi-Chang Chen, PhD, PharmD, MS3. P0879 - Ozanimod Adherence in Patients With Ulcerative Colitis in the United States, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.
